Caris Life Sciences Inc.
CAI evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $8.74B
- Lead Asset:
- caris assure (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CAI
Caris Life Sciences Inc. (CAI) is a next-generation AI TechBio company and precision medicine pioneer that develops and commercializes solutions using comprehensive molecular information and AI/machine learning algorithms to transform healthcare [sec_mda · as of 2025-06-16].
Key risk: Net loss persists
BioSniper Score
Based on 4 of 6 signals
Market Cap
$8.74B
Cash Runway
—
Lead Asset
caris assure (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Caris Life Sciences Inc..
Caris Life Sciences Inc. (CAI) is a next-generation AI TechBio company and precision medicine pioneer that develops and commercializes solutions using comprehensive molecular information and AI/machine learning algorithms to transform healthcare [sec_mda · as of 2025-06-16].
- Total revenue of $263.7M for the three months ended June 30, 2026, compared to $181.4M in the same period of 2025 [sec_mda · as of 2026-08-05].
- Net loss of $0.6M for the three months ended June 30, 2026, compared to a net loss of $71.8M in the same period of 2025 [sec_mda · as of 2026-08-05].
- Cash, cash equivalents, restricted cash and marketable securities of $794.9 million as of June 30, 2026 [sec_mda · as of 2026-08-05].
- Aggregate principal amount of debt outstanding under existing term loan was $400.0 million as of June 30, 2026 [sec_mda · as of 2026-08-05].
- Shareholders' equity of $591.7M as of 2026-06-30 [latest reported financials].
What works
- Revenue growth: total revenue increased from $181.4M to $263.7M year-over-year for the quarter ended June 30, 2026 [sec_mda · as of 2026-08-05].
- Substantial cash reserves: $794.9 million in cash and equivalents as of June 30, 2026 provide a strong liquidity position [sec_mda · as of 2026-08-05].
- Narrowing net loss: net loss reduced from $71.8M to $0.6M year-over-year for the quarter ended June 30, 2026 [sec_mda · as of 2026-08-05].
- Positive Adjusted EBITDA: $55.7 million for the three months ended June 30, 2026, up from $16.7 million in the prior year [sec_mda · as of 2026-08-05].
What to weigh
- Continued net losses: the company reported a net loss of $0.6M for the quarter ended June 30, 2026 [sec_mda · as of 2026-08-05].
- Significant debt: $400.0 million in term loan debt outstanding as of June 30, 2026 [sec_mda · as of 2026-08-05].
- Potential need for additional capital: the company may need to raise additional capital through equity or debt financings [sec_mda · as of 2026-08-05].
- Stock price decline: the stock is down 28.06% on a 1-year total shareholder return basis [news · published 2026-09-06].
From the filings
Quoted directly from source documents.
Revenue and net loss for Q2 2026
“For the three months ended June 30, 2026 and 2025, we generated total revenue of $263.7 million and $181.4 million, respectively, and incurred a net loss of $0.6 million and $71.8 million, respectively.”
SEC MD&A · August 5, 2026
Cash and debt position as of June 30, 2026
“of June 30, 2026, we had cash, cash equivalents, restricted cash and marketable securities of $794.9 million, and the aggregate principal amount of debt outstanding under our existing term loan was $400.0 million.”
SEC MD&A · August 5, 2026
Company description as a precision medicine pioneer
“We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer.”
SEC MD&A · June 16, 2025
Adjusted EBITDA for Q2 2026
“Our Adjusted EBITDA was $55.7 million and $16.7 million for the three months ended June 30, 2026 and 2025, re”
SEC MD&A · August 5, 2026
Risks & what to watch (4)›
Key risks
- Net loss persists — The company reported a net loss of $0.6M for Q2 2026, indicating continued unprofitability [sec_mda · as of 2026-08-05].
- High debt burden — $400.0 million in term loan debt outstanding as of June 30, 2026 [sec_mda · as of 2026-08-05].
- Potential capital needs — The company may need to raise additional capital through equity or debt financings [sec_mda · as of 2026-08-05].
- Stock price decline — Stock down 28.06% on a 1-year total shareholder return basis [news · published 2026-09-06].
What to watch
- Presentation of seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul [news · published 2026-09-06].
- August 2026 pancreatic cancer AI publication [news · published 2026-09-06].
- Trend in net loss and Adjusted EBITDA in upcoming quarterly reports [sec_mda · as of 2026-08-05].
- Any changes in cash position and debt levels in future SEC filings [sec_mda · as of 2026-08-05].
Sources: News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Caris Life Sciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Caris Life Sciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.08 · 0% dilution
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 11.1%
- Days to cover
- 7.0
- Shares short
- 12,733,076
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Caris Life Sciences Inc.?
Caris Life Sciences Inc. (CAI) is a next-generation AI TechBio company and precision medicine pioneer that develops and commercializes solutions using comprehensive molecular information and AI/machine learning algorithms to transform healthcare [sec_mda · as of 2025-06-16].
What is Caris Life Sciences Inc.'s lead drug candidate?
Caris Life Sciences Inc.'s most advanced tracked candidate is caris assure (Preclinical) for Minimal residual disease tracking and treatment monitoring.
Who is the CEO of Caris Life Sciences Inc.?
Dr. David Dean Halbert M.D. is the chief executive officer of Caris Life Sciences Inc. (CAI).
Where is Caris Life Sciences Inc. headquartered?
Caris Life Sciences Inc. (CAI) is headquartered in Irving, TX, United States.
What therapeutic areas does Caris Life Sciences Inc. focus on?
Caris Life Sciences Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.